Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead of Special Meeting of Stockholders Jul 23, 2021 7:00am EDT
Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research Jul 12, 2021 7:00am EDT
Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical Jul 08, 2021 7:10am EDT
Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects Jul 07, 2021 7:00am EDT
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder Jun 16, 2021 7:00am EDT
Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021 May 19, 2021 7:00am EDT
Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting May 12, 2021 7:00am EDT
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial May 06, 2021 7:03am EDT
